• #LGM Pharma is a Clioquinol CAS# 130-26-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 130-26-7
  • AHFC code:
  • Synonyms: 5-Chlor-7-jod-8-hydroxy-chinolin [German] 5-Chloro-7-iodo-8-hydroxyquinoline 5-Chloro-7-iodo-8-quinolinol 5-Chloro-7-iodoquinolin-8-ol 5-Chloro-8-hydroxy-7-iodoquinoline 7-Iodo-5-chloro-8-hydroxyquinoline 7-Iodo-5-chloroxine Caswell No. 193 Chloro-8-hydroxyiodoquinoline Chloroiodoquin Chloroiodoquine Cliochinolo [dcit] Clioquinolum [inn-latin] IODO Iodochlorhydroxyquin Iodochlorhydroxyquinol Iodochlorhydroxyquinoline Iodochlorohydroxyquin Iodochlorohydroxyquinoline Iodochloroquine Iodochloroxine Iodochloroxychinolinum Iodochloroxyquinoline Iodoxyquinoline Jodchloroxychinolinum
  • ATC Code: P01AA02 D08AH30 S02AA05 G01AC02 D09AA10
  • Chemical Formula: C6H10N6O
  • Molecular Weight: 305.5
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB04815
  • SMILES: OC1=C(I)C=C(Cl)C2=C1N=CC=C2
  • PubChem: 2788
  • IUPAC: 5-chloro-7-iodoquinolin-8-ol

Additional Details

Used as a topical antifungal treatment.
Clioquinol is a broad-spectrum antibacterial with antifungal properties. Application of clioquinol to extensive or eroded areas of the skin may lead to increased protein-bound iodine (PBI) levels within 1 week. In addition, elevated PBI levels may occur when relatively small areas of the skin are treated with clioquinol for more than 1 week.
Mode of Action:
Clioquinol is bacteriostatic, however, the precise mechanism of its action is unknown.
General Reference:
Rohde W, Mikelens P, Jackson J, Blackman J, Whitcher J, Levinson W: Hydroxyquinolines inhibit ribonucleic acid-dependent deoxyribonucleic acid polymerase and inactivate Rous sarcoma virus and herpes simplex virus. Antimicrob Agents Chemother. 1976 Aug;10(2):234-40. Pubmed GHOLZ LM, ARONS WL: PROPHYLAXIS AND THERAPY OF AMEBIASIS AND SHIGELLOSIS WITH IODOCHLORHYDROXYQUIN. Am J Trop Med Hyg. 1964 May;13:396-401. Pubmed Kager PA: [Outbreak of amoebiasis in a Dutch family; tropics unexpectedly nearby] Ned Tijdschr Geneeskd. 2005 Jan 1;149(1):51-2; author reply 52-3. Pubmed Bosman DK, Benninga MA, van de Berg P, Kooijman GC, van Gool T: [Dientamoeba fragilis: possibly an important cause of persistent abdominal pain in children] Ned Tijdschr Geneeskd. 2004 Mar 20;148(12):575-9. Pubmed Masters DK, Hopkins AD: Therapeutic trial of four amoebicide regimes in rural Zaire. J Trop Med Hyg. 1979 May;82(5):99-101. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials


Related YouTube Videos